Natco Pharma Fixes ₹750 Price For ₹1,279 Crore 2:21 Rights Issue

Board approved rights issue of 1.71 Cr shares at Rs 750 per share aggregating Rs 1279.36 Cr in 2-for-21 ratio. Record Oct 1 2026; issue Oct 12-22, renunciation Oct 12-16. Fixes pending price, ratio and timetable; first equity raise since listing, shifting from self-funded profile to fund debt repayment, R&D and inorganic growth. Adds about 9.5% new shares if fully subscribed; discount, subscription outcome, final allotment and balance use not disclosed; demerger revision still pending.